Bayer: Science For A Better Life

United States of America

Stroke Prevention

Stroke Prevention

Intended Format: Grand Rounds – Live/Enduring, Minute-CME/CME Blast, other

Intended Audience: Cardiologist, Neurologist, Primary Care Physician, Critical Care Physician, Hospitalist, Advanced Practice Providers, Nurse, Pharmacist, Care Manager

Bayer TA Rationale for Educational Support:

Highest priority will be given to programs whose main focus is:

  • Raise awareness of the unmet need for treatments with an improved safety profile and equivalent or superior efficacy to current treatment options with regard to major bleeds
  • Establish FXIa inhibition as a new and distinct class of antithrombotic
  • Differentiate fXa inhibition/inhibitors and versus fXIa inhibitors
  • Discuss the significance of fXIa inhibition as a novel antithrombotic which can address current unmet needs
  • Communicate residual stroke risk (SSP) and bleeding risk (AF) to providers, including patients who may be suboptimally managed because of bleeding risk
  • Review data sets: PACIFIC-STROKE and PACIFIC-AF
  • Differentiating vs DOACs (e.g., not just another DOAC
  • Discuss current guidelines and the burden of undertreatment and non-treatment of patients with elevated stroke risk, highlighting the need for safer treatment options
  • Burden of illness of stroke

Proposal Requirements:

The proposal must be compliant with standards and guidelines for commercial support (e.g., ACCME).

The proposal should include:

  • Needs assessment
  • Educational design and rationale for selection (where applicable)
  • Learning Objectives
  • Proposed Faculty
  • Participant recruitment plan (where applicable)
  • Outcomes strategy/plan
  • Detailed budget

Provider Justification:

Copy of most recent accreditation letter and status


Applications/proposals which are submitted and determined to be complete are reviewed monthly. Allow a minimum of 45 days from submission for response.

Acceptance of a Bayer educational grant indicates that you will:

  • Reconcile grant funding within 60 days of completion of the educational program
  • Permit a Bayer Medical Affairs representative to audit live programs
  • Share activity data and outcomes metrics within 30 days of their availability


  • Piccini JP, Caso V, Connolly SJ, Fox KAA, Oldgren J, Jones WS, Gorog DA, Durdil V, Viethen T, Neumann C, Mundl H, Patel MR; PACIFIC-AF Investigators. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet. 2022 Apr 9;399(10333):1383-1390. doi: 10.1016/S0140-6736(22)00456-1. Epub 2022 Apr 3. PMID: 35385695.
  • Shoamanesh A, Mundl H, Smith EE, Masjuan J, Milanov I, Hirano T, Agafina A, Campbell B, Caso V, Mas JL, Dong Q, Turcani P, Christensen H, Ferro JM, Veltkamp R, Mikulik R, De Marchis GM, Robinson T, Lemmens R, Stepien A, Greisenegger S, Roine R, Csiba L, Khatri P, Coutinho J, Lindgren AG, Demchuk AM, Colorado P, Kirsch B, Neumann C, Heenan L, Xu L, Connolly SJ, Hart RG; PACIFIC-Stroke Investigators. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet. 2022 Sep 24;400(10357):997-1007. doi: 10.1016/S0140-6736(22)01588-4. Epub 2022 Sep 2. PMID: 36063821.
  • Sussman M, Barnes GD, Guo JD, Tao CY, Gillespie JA, Ferri M, Adair N, Cato MS, Shirkhorshidian I, Di Fusco M. The burden of undertreatment and non-treatment among patients with non-valvular atrial fibrillation and elevated stroke risk: a systematic review. Curr Med Res Opin. 2022 Jan;38(1):7-18. doi: 10.1080/03007995.2021.1982684. Epub 2021 Oct 9. PMID: 34632887.
  • Greco A, Laudani C, Spagnolo M, Agnello F, Faro DC, Finocchiaro S, Legnazzi M, Mauro MS, Mazzone PM, Occhipinti G, Rochira C, Scalia L, Capodanno D. Pharmacology and Clinical Development of Factor XI Inhibitors. Circulation. 2023 Mar 14;147(11):897-913. doi: 10.1161/CIRCULATIONAHA.122.062353. Epub 2023 Mar 13. PMID: 36913497.
  • January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019 Jul 9;140(2):e125-e151. doi: 10.1161/CIR.0000000000000665. Epub 2019 Jan 28. Erratum in: Circulation. 2019 Aug 6;140(6):e285. PMID: 30686041.
  • GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021 Oct;20(10):795-820. doi: 10.1016/S1474-4422(21)00252-0. Epub 2021 Sep 3. PMID: 34487721; PMCID: PMC8443449.